Pancreatic Cancer Research

ResearcherWuhan UniversityActive in the last 2 years

Hanjun Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7017-8782; OpenAlex author ID A5071554167. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 5

  1. UPP1 and AHSA1 as emerging biomarkers and targets in pancreatic cancer: A proteomic approach. Last author DOI 10.17305/bb.2025.11958↗
  2. CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway. Co-author DOI 10.1007/s10565-022-09746-w↗
  3. microRNA-21-5p from M2 macrophage-derived extracellular vesicles promotes the differentiation and activity of pancreatic cancer stem cells by mediating KLF3. First author DOI 10.1007/s10565-021-09597-x↗
  4. Circular RNA CDR1as promotes tumor progression by regulating miR-432-5p/E2F3 axis in pancreatic cancer. Co-author DOI 10.1186/s12935-021-01812-3↗
  5. Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a positive feedback loop with AKT/HIF-1α sig… Co-author PMID 33520364↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jing Tao · 4 shared papers, 2021–2023 · strength 0.65
  2. Kongfan Zhu · 1 shared paper, 2025 · strength 0.33
  3. Zhi‐Gang Tang · 2 shared papers, 2021–2023 · strength 0.32
  4. Zhengle Zhang · 2 shared papers, 2021–2023 · strength 0.32
  5. Jian Hua Chang · 2 shared papers, 2021–2022 · strength 0.32
  6. Xingcheng Xiong · 2 shared papers, 2021–2022 · strength 0.32
  7. Pei Mei · 2 shared papers, 2021–2022 · strength 0.29
  8. Longjiang Chen · 1 shared paper, 2023 · strength 0.20
  9. Weimin Hu · 1 shared paper, 2022 · strength 0.17
  10. Hehe Li · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.